What Does Waters (WAT) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Waters (WAT) is a global analytical instrumentation leader headquartered in Massachusetts, USA. Equipment revenue from liquid chromatography and mass spectrometers, the expansion of biopharma lifecycle services, and the rising share of recurring revenue from consumables and software are the core drivers shaping its stock price.
🏢 What kind of company is Waters?
Waters (WAT) is a global analytical instrumentation company founded in 1958 and headquartered in Milford, Massachusetts, USA. Since its founding, the company has focused on liquid chromatography and mass spectrometry, establishing itself as a key player in the analytical sciences market.
The Waters segment supplies liquid chromatography, ultra-performance liquid chromatography, mass spectrometry, precision chemistry consumables, software, and services, while the TA segment operates thermal analysis, rheology, and calorimetry instruments. Its primary customer base spans analytical infrastructure across pharmaceutical, biotech, food, environmental, and materials sectors.
How does Waters make money?| Business Segment | Revenue Weight | Description |
|---|---|---|
| Analytical Instrumentation Equipment | Core | Liquid chromatography, mass spectrometry, and thermal analysis equipment |
| Consumables & Precision Chemistry | Key Growth Driver | Recurring revenue from instrument columns and dedicated chemistry consumables |
| Services & Software | Expanding | Long-term service contracts and data software licenses |
| TA Segment | Diversification Driver | Thermal analysis, rheology, and materials analysis equipment |
Recent annual revenue shows a stable growth trend, combining equipment sales with recurring revenue from consumables and services. A recovery in analytical infrastructure demand from the biopharma sector and the expansion of lifecycle services support revenue diversification, while a rising share of consumables and software strengthens margin stability. Global sales coverage combined with precision chemistry and software integrated solutions contributes to customer lock-in, supporting long-term revenue visibility.
📐 Waters Market Cap and Company Scale
Market capitalization stands at $37.3B, and the company employs 7,900명 people.
As a large-cap name in the global analytical instrumentation field, Waters sits within the top tier of healthcare tools and diagnostics groups. Within its peer category, it is grouped with large life sciences tools companies in analytical instrumentation such as A, TMO, and DHR, and has historically leveraged share buybacks and M&A as capital return and external growth drivers, backed by stable free cash flow.
📈 Waters Outlook and Stock Price Trends
A recovery in biopharma analytical infrastructure investment and the expansion of lifecycle services are the key medium- to long-term growth drivers. A rising share of recurring revenue from consumables and software, growing analytical demand from environmental and food sectors, and business expansion through M&A all contribute to top-line growth. In the short term, variability factors include the global pharma and biotech capital investment cycle, the pace of recovery in the China market, FX volatility, and M&A integration costs.
- Expanding biopharma analytical infrastructure demand
- Rising share of recurring revenue from consumables and software
- Diversification through lifecycle services and M&A
⚔️ Waters Core Strengths and Risks
A leading position in analytical instrumentation and a recurring revenue structure from consumables and services are strengths, while the pharma and biotech capital investment cycle represents the key risk.
💪 Core Strengths
⚠️ Core Risks
🔄 Waters Competitors and Related Stocks (Beneficiaries)
Direct competitors include A (Agilent Technologies) in comprehensive analytical instrumentation, TMO (Thermo Fisher Scientific) in global life sciences tools, and DHR (Danaher) in diversified precision instrumentation and diagnostics. Related names include BIO and MTD in adjacent analytical instrumentation, as well as KEYS in precision instrumentation and test equipment, all of which share the analytical instrumentation cycle.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| A | Agilent Technologies Inc | $140.30 | -0.2% | $39.6B | 28.2 | 5.6 | 21.33% | 0.73% |
| TMO | Thermo Fisher Scientific Inc | $576.46 | +0.0% | $214.2B | 31.0 | 4.1 | 13.53% | 0.32% |
| DHR | Danaher Corp | $196.49 | -1.3% | $138.1B | 34.9 | 2.6 | 7.61% | 0.73% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 BIO | Bio-Rad Laboratories Inc | $327.25 | -1.1% | $8.8B | 53.9 | 1.3 | 2.5% | - |
 MTD | Mettler-Toledo International Inc | $1388.33 | +0.0% | $28.1B | 32.6 | - | - | - |
| KEYS | Keysight Technologies Inc | $296.72 | -2.8% | $50.7B | 48.9 | 8.0 | 18.17% | - |
✅ Investor Checkpoints for Waters
Key points to monitor when investing in Waters. The recovery in biopharma analytical infrastructure demand, the rising share of recurring revenue from consumables and services, and the pace of China market recovery are the key short- and medium-term variables.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 📈 Equipment Revenue | Recovery trend in liquid chromatography and mass spectrometry sales | Recovering phase |
| 🔁 Recurring Revenue | Trend in the revenue share of consumables, services, and software | Expanding trend |
| 🌏 China Market | Pace of revenue recovery in the China analytical instrumentation market | Needs monitoring |
| 💰 Capital Return | Progress of share buybacks and M&A activity | Ongoing trend |
A slowdown in global pharma and biotech capital investment and a delay in China market recovery are short-term revenue headwinds. The large share of overseas revenue means FX volatility can affect translated revenue and margins, and large-scale M&A integration costs and intangible asset amortization may weigh on short-term earnings.
Waters is a high-quality global life sciences tools name combining a leading position in analytical instrumentation with a recurring revenue structure from consumables and services. The pharma and biotech capital investment cycle, the share of recurring revenue, and the China recovery are the key variables to monitor, and a phased accumulation approach with a long-term perspective is recommended.
이 글은 2026년 5월 21일 기준 정보입니다.